Literature DB >> 18047354

Synthetic and biosynthetic studies on FR900482 and mitomycin C: an efficient and stereoselective hydroxymethylation of an advanced benzazocane intermediate.

Hidenori Namiki1, Stephen Chamberland, Daniel A Gubler, Robert M Williams.   

Abstract

We report a simple, efficient, and stereoselective Mukaiyama aldol approach to install the key hydroxymethyl moiety into the benzazocane framework of FR900482. Synthetic investigations revealed that the reaction is highly dependent upon the electronics of the aromatic ring. This approach enabled the economical introduction of a [13C] label to study the biosynthesis of these structurally and biogenetically related natural products. Epimerization of the initially formed beta-hydroxy ketone may enable access to mitomycin C or FR900482 biosynthetic congeners.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18047354      PMCID: PMC2566745          DOI: 10.1021/ol701960v

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  11 in total

1.  DNA Cross-Linking Agents as Antitumor Drugs.

Authors:  Scott R. Rajski; Robert M. Williams
Journal:  Chem Rev       Date:  1998-12-17       Impact factor: 60.622

2.  Concise enantioselective synthesis of (+)-FR66979 and (+)-FR900482: dimethyldioxirane-mediated construction of the hydroxylamine hemiketal.

Authors:  Ted C Judd; Robert M Williams
Journal:  Angew Chem Int Ed Engl       Date:  2002-12-16       Impact factor: 15.336

Review 3.  Mechanisms of in situ activation for DNA-targeting antitumor agents.

Authors:  Scott E Wolkenberg; Dale L Boger
Journal:  Chem Rev       Date:  2002-07       Impact factor: 60.622

4.  A concise total synthesis of (+)-FR900482 and (+)-FR66979.

Authors:  Ted C Judd; Robert M Williams
Journal:  J Org Chem       Date:  2004-04-16       Impact factor: 4.354

5.  Differential effects of FR900482 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome.

Authors:  Lois Beckerbauer; Jetze J Tepe; Rebecca A Eastman; Philip F Mixter; Robert M Williams; Raymond Reeves
Journal:  Chem Biol       Date:  2002-04

6.  FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo.

Authors:  L Beckerbauer; J J Tepe; J Cullison; R Reeves; R M Williams
Journal:  Chem Biol       Date:  2000-10

7.  Enantioselective total synthesis of FR900482.

Authors:  Masashi Suzuki; Mika Kambe; Hidetoshi Tokuyama; Tohru Fukuyama
Journal:  J Org Chem       Date:  2004-04-16       Impact factor: 4.354

8.  Catalytic asymmetric hydroxymethylation of silicon enolates using an aqueous solution of formaldehyde with a chiral scandium complex.

Authors:  Shunpei Ishikawa; Tomoaki Hamada; Kei Manabe; Shū Kobayashi
Journal:  J Am Chem Soc       Date:  2004-10-06       Impact factor: 15.419

9.  Formal enantiospecific synthesis of (+)-FR900482.

Authors:  M Rita Paleo; Natalia Aurrecoechea; Kang-Yeoun Jung; Henry Rapoport
Journal:  J Org Chem       Date:  2003-01-10       Impact factor: 4.354

10.  DNA and the chromosome - varied targets for chemotherapy.

Authors:  Stephanie M Nelson; Lynnette R Ferguson; William A Denny
Journal:  Cell Chromosome       Date:  2004-05-24
View more
  4 in total

1.  Synthetic Studies Towards the Mitomycins: Construction of the Tetracyclic Core via a Reductive Aminocyclization Reaction.

Authors:  Daniel A Gubler; Robert M Williams
Journal:  Tetrahedron Lett       Date:  2009-07-22       Impact factor: 2.415

2.  Synthesis of potential early-stage intermediates in the biosynthesis of FR900482 and mitomycin C.

Authors:  Stephen Chamberland; Sabine Grüschow; David H Sherman; Robert M Williams
Journal:  Org Lett       Date:  2009-02-19       Impact factor: 6.005

Review 3.  Biosynthesis of DNA-Alkylating Antitumor Natural Products.

Authors:  Qiu-Yue Nie; Yu Hu; Xian-Feng Hou; Gong-Li Tang
Journal:  Molecules       Date:  2022-09-27       Impact factor: 4.927

4.  Mitomycins syntheses: a recent update.

Authors:  Jean-Christophe Andrez
Journal:  Beilstein J Org Chem       Date:  2009-07-08       Impact factor: 2.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.